RAS

Events

Partner Content

For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible.

News

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.